Discussed E-Posters & E-Posters
Discussed E-Posters
P030
HIGH AND DURABLE CLEARANCE THROUGH 52 WEEKS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
M.Gooderham *, M.Lebwohl , K.Gordon , T.Wu , H.Photowala , H.Bachelez (Peterborough, Canada)
P031
EFFICACY OF SWITCHING TO RISANKIZUMAB COMPARED WITH CONTINUED ADALIMUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
C.Ryan *, J.Crowley , W.Valdecantos , T.Wu , K.Reich (Dublin, Ireland)
P032
SAFETY OF CERTOLIZUMAB PEGOL IN PLAQUE PSORIASIS: POOLED 96-WEEK DATA FROM THREE PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDIES (CIMPASI-1, CIMPASI-2 AND CIMPACT)
A.Blauvelt *, B.Strober , R.Langley , S.Kavanagh , C.Arendt , M.Boehnlein , M.Lebwohl , K.Reich (Portland, United States)
P033
THE RISK OF PARKINSON’S DISEASE IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY
J. H.Lee *, K.Han , H. Y.Gee (Seoul, Korea, Republic Of)
P034
ALZHEIMER’S DISEASE RISK IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY
J. H.Lee *, S.-H.Lee , K.Han , M.Kim (Seoul, Korea, Republic Of)
P035
COEXISTENCE OF ONYCHOMYCOSIS IN PSORIATIC NAILS AND ITS CORRELATION WITH NAIL PSORIATIC SEVERITY INDEX AND PSORIASIS TREATMENT
S.Carneiro *, R.Grynszpan , A.Arnóbio , M.Fernandes , M.Paixão , A.Pessoa , M.Ramos-e-Silva (Rio de Janeiro, Brazil)
P036
ANTINUCLEAR ANTIBODIES IN PATIENTS WITH BEHCET'S SYNDROME
K.Khalidova *, D.Porsokhonova , Y.Alimukhamedova (Tashkent, Uzbekistan)
P037
THE ROLE OF IMMUNE DISORDERS IN THE DEVELOPMENT OF IDIOPATHIC TYPE OF
KAPOSI'S SARCOMA
K.Khalidova *, G.Ismailova (Tashkent, Uzbekistan)
P038
ANALYSIS OF IMMUNOLOGICAL ASSOCIATION BETWEEN
LATENT TUBERCULOSIS INFECTION AND PSORIASIS
C. J.Park *, J. Y.Hong , J. H.Kim , J. R.Hong , H. I.Cheon , M. S.Hur , Y. W.Lee , Y. B.Choe , K. J.Ahn (Bucheon, Korea, Republic Of)
P039
TREATMENT SWITCHING AMONG PSORIASIS PATIENTS TREATED WITH IXEKIZUMAB, SECUKINUMAB, AND ADALIMUMAB IN REAL-WORLD SETTINGS
A.Blauvelt , N.Shi , R.Burge , W. N.Malatestinic , C. R.Lew , N. M.Zimmerman , D.Amato , B.Zhu , M. J.Murage * (Indianapolis, IN, United States)
P041
GENERALIZED PUSTULAR PSORIASIS IN THE SOUTH OF TUNISIA: 44CASES.
G.Hela *, B.Emna , N.Mariem , B.Noura , B.Sonia , M.Abderrahmen , M.Slaheddine , T.Hamida (Sfax, Tunisia)
P042
IMPACT OF MIRIKIZUMAB TREATMENT ON PSORIASIS DISEASE ACTIVITY AT WEEK 52 BASED UPON PRIOR TREATMENT WITH BIOLOGIC THERAPY
P.Rich *, A.Igarashi , D.Patel , P.Klekotka , J.Li , J.Tuttle , C.Maari (Portland, United States)
P043
OPTIMIZING ADALIMUMAB TREATMENT IN PSORIASIS WITH CONCOMITANT METHOTREXATE: A RANDOMIZED CONTROLLED TRIAL
G.Van Der Kraaij *, C.Busard , J.van den Reek , S.Menting , E.de Jong , W.de Kort , J.Lambert , P.Spuls (Amsterdam, Netherlands)
P044
EFFICACY OF MIRIKIZUMAB (LY3074828) AFTER STRATIFYING BY BASELINE PSORIASIS SEVERITY: POST HOC ANALYSIS OF A RANDOMIZED PHASE 2 STUDY
J.Bagel *, M.Gooderham , H.Sonnergren , B.Zhu , V.Arora , P.Klekotka , A.Egeberg (Windsor, United States)
P045
BIPE (BIOLOGICAL TREATMENTS FOR PPAEDIATRIC PSORIASIS): A RETROSPECTIVE OBSERVATIONAL STUDY ON BIOLOGICAL DRUG SURVIVAL IN DAILY PRACTICE IN CHILDHOOD PSORIASIS
C.Phan *, A.Beauchet , A. C.Bursztejn , S.Barbarot , C.Girard , A.Lasek , S.Hadj-Rabia , C.Abasq , C.Droitcourt , S.Mallet , A.Phan , J.-P.Lacour , E.Bourrat , G.Chaby , P.Plantin , A.Maruani , M.Piram , F.Maccari , A. C.Fougerousse , H.Barthélémy , L.Martin , L.Mery-Bossard , V.Pallure , D.Lons-Danic , E.Puzenat , M.Beylot-Barry , D.Bouilly-Auvray , F.Aubin , E.Mahé et the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, and the Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie (Argenteuil, France)
P046
PROFILIN-1 AS A POSSIBLE BIOMARKER IN PSORIASIS
D. H.Kim *, I. J.Jeong , S. H.Baek , H. J.Lee , M. S.Yoon , T.-A.Kim (Seongnam, Korea, Republic Of)
P047
EXPRESSION OF SIRTUIN 1 AND INTERFERON GAMMA IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH NB-UVB PHOTOTHERAPY
O.Sorour , A.Eid *, S.Elkholy , R.Ali (Alexandria, Egypt)
P048
REAL WORLD USE OF SECUKINUMAB IN DIFFICULT TO TREAT PLAQUE PSORIASIS IN INDIAN PATIENTS: A 72 WEEK SINGLE CENTRE RETROSPECTIVE STUDY
S.Madanagobalane * (Chennai, India)
P049
CROSS-SWITCH FROM CT-P13 TO SB2 INFLIXIMAB BIOSIMILARS IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS
P.Gisondi *, C.Virga , G.Girolomoni (VERONA, Italy)
P050
FLEXIBLE ADALIMUMAB DOSING IN MODERATE TO SEVERE PSORIASIS - THERAPEUTICAL OPTION
T.Pecova *, J.Pec (Martin, Slovakia)
P051
ASSESSING THE DIFFERENCES BETWEEN PSORIASIS PATIENTS WHO ARE ALIGNED WITH THEIR PHYSICIAN ON THEIR CURRENT DISEASE SEVERITY VERSUS PATIENTS WHO ARE MISALIGNED
M.Murage *, O.Goldblum , C.-Y.Lin , L.Renda , S.Lobosco , J.Lucas , C.Middleton , N.Korman (Indianapolis, United States)
P052
POTENTIAL OF HIGH-FREQUENCY ULTRASONOGRAPHY IN MONITORING PSORIASIS
A. N.Boca *, R. F.Ilies , M. C.Somlea , A.Tataru (Cluj-Napoca, Romania)
P053
EARLY TREATMENT TARGETS FOR PREDICTING LONG-TERM DERMATOLOGY LIFE QUALITY INDEX RESPONSE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: A POST HOC ANALYSIS FROM A LONG-TERM CLINICAL STUDY
L.Puig *, B.Zhu , R.Burge , D.Shrom , D.Amato , Y.Dong , W.Shen , L.Mallbris , K.Reich (Barcelona, Spain)
P054
IXEKIZUMAB PROVIDES PERSISTENT IMPROVEMENT IN THE SYMPTOMS OF GENITAL PSORIASIS THROUGH ONE YEAR OF TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS
C.Ryan *, R.Burge , Y.Poulin , L.Spelman , A.Potts Bleakman , F. E.Yang , C. C.Bertram , L.Guenther (Dublin, Ireland)
P055
MAINTENANCE OF RESPONSE THROUGH UP TO 3-YEARS OF CONTINUOUS GUSELKUMAB TREATMENT OF PSORIASIS IN THE VOYAGE 2 PHASE 3 TRIAL
K.Reich *, M.Song , B.Randazzo , S.Li , Y.-K.Shen , C.Han , A.Armstrong , P.Foley , K. B.Gordon (Hamburg, Germany)
P056
COMPARABLE AND CONSISTENT EFFICACY RESPONSES WITH UP TO 3 YEARS OF GUSELKUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS REGARDLESS OF PRIOR TREATMENT: POOLED ANALYSIS FROM THE VOYAGE 1 AND VOYAGE 2 TRIALS
K.Gordon *, L.Guenther , A.Pinter , Y.-B.Choe , M.Song , S.Li , S.Fakharzadeh , Y.-K.Shen , T.-F.Tsai (Milwaukee, United States)
P057
MIR-146A EXPRESSION IN PERIPHERAL CD14+ MONOCYTES CORRELATES WITH DISEASE SEVERITY IN PATIENTS WITH PSORIATIC ARTHRITIS: AN EARLY DIAGNOSTIC BIOMARKER
C.-H.Lee *, S.-H.Lin , C.-H.Hong (Kaohsiung, Taiwan)
P058
TIME UNTIL ONSET OF ACTION WHEN TREATING PSORIATIC ARTHRITIS: SYSTEMATIC REVIEW AND META-ANALYSIS
A.Nast *, P. A.Pham , R. N.Werner , C.Dressler (Berlin, Germany)
P059
A STRATEGY OF MULTIDISCIPLINARY DIAGNOSIS OF PSORIATIC ARTHRITIS
C.Rincón-Pérez *, R.Montes-Cruz , L.Rodríguez-Jiménez , O.Muñoz-Monroy , B.Mota-Mondragón , G.Aguilar , M. L.Morales-Trujillo , R.Rodríguez-Romo (Mexico City, Mexico)
P060
EFFICACY AND SAFETY OF PHOTOTHERAPY IN THE ERA OF TARGETED BIOLOGICAL THERAPIES.
J. M.Ortiz Salvador *, M.Saneleuterio Temporal , J.Magdaleno Tapial , A.Pérez Ferriols (valencia, Spain)
P061
DISCONTINUATION RATES FOR BIOLOGIC THERAPIES IN MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS IN A REAL-WORLD CANADIAN PATIENT COHORT
S.Gulliver , W.Gulliver *, S.Randell (St. John's, Canada)
P062
EVALUATION OF CARCINOGENIC RISK OF PUVA VERSUS RE-PUVA IN PSORIATIC PATIENTS
H.Mashaly *, M.Fathy Hussein , S.Hamdy , O.Shaker (Cairo, Egypt)
P063
THE ROLE AND RELATIONSHIP OF PLASMA D-DIMER LEVEL AND AUTOLOGOUS SERUM SKIN TEST IN THE CHRONIC SPONTANEOUS URTICARIA
B.Park *, K.Kim , E.Hong (Gyeonggi-do, Korea, Republic Of)
P064
WOULD CHILDREN TREATED WITH BIOTHERAPIES IN PSORIASIS, IN REAL-LIFE PRACTICE, BE ELIGIBLE FOR PHASE III CLINICAL STUDIES? EVALUATION FROM THE BIPE COHORT
C. Phan *, A. Beauchet, A.C. Bursztejn, S. Barbarot, C. Girard, A. Lasek, S. Hadj-Rabia, C. Abasq, C. Droitcourt, S. Mallet, A. Phan, J.-P. Lacour, Z. Bourrat, G. Chaby, F. Aubin, Z. Mahé and le Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, et le Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie (Argenteuil, France)
P065
MANAGEMENT OF PSORIASIS USING BASIC TOOLS IN RESOURCE POOR SETUP : A STUDY OF 33 PATIENTS WITH CO MORBID CONDITIONS FOLLOWED UP FOR 5 YEARS AND 3 MONTHS.
V.Singh * (DELHI, India)
P066
EXPOSURE-EFFICACY RESPONSE MODELLING OF BMS-986165, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 STUDY IN PSORIASIS
I.Girgis *, A.Chimalakonda , S.Kundu , J.Throup , S.Banerjee (Princeton, United States)
P067
THE EFFECT OF GUSELKUMAB ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 STUDY
A. B.Gottlieb *, B.Wolf-Henning , P.Helliwell , A.Deodhar , X. L.Xu , S.Xu , Y.Wang , Y.Zhuang , E.Hsia (New York, United States)
P068
SHORT- AND LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: AN INTEGRATED ANALYSIS
H.Bachelez *, K.Gordon , A.Blauvelt , J.Wu , R.Sinvhal , H.Photowala , J.Valdes , B.Waterhouse , M.Lebwohl , K.Reich (Paris, France)
P069
COMPLETE CLEARANCE AND CUMULATIVE BENEFIT BY PSORIASIS AREA AND SEVERITY INDEX (PASI) FOR BRODALUMAB AND USTEKINUMAB IN AMAGINE-2 AND -3
R.Warren *, J.Hansen , V.Schultz Nielsen , L.Puig (Salford, United Kingdom)
P070
THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PRCL-02 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC PLAQUE PSORIASIS
M.Gooderham , K. A.Papp *, R.Larouche , E.Raddad , J.Sloan-Lancaster , J.Bingham , P.Clermont , Z. P.Neeb , C.Fortier (Waterloo, Canada)
P071
APREMILAST IN PALMOPLANTAR PSORIASIS
P. M.Josep * (Tarragona, Spain)
P072
WHICH ANTIPSORIATIC INDUCTION TREATMENT SEQUENCE IS THE MOST TIME-EFFECTIVE? ECONOMIC MODELLING WITH TIME INSTEAD OF MONETARY COST
M.Zidane , C.Dressler , M.Gaskins , A.Nast * (Berlin, Germany)
P073
ASSESSING QUALITY OF LIFE AFFECTION WITH POEM, DLQI, AND QOLIAD, CORRELATED WITH EASI IN ADULT PATIENTS WITH ATOPIC DERMATITIS. WHICH ONE SHOULD WE USE?
U.Villela-Segura *, G.De León-Dorantes , A.Mercado-Lara , E.Guevara-Sangines (Mexico City, Mexico)
P078
TILDRAKIZUMAB EFFECT ON CARDIOMETABOLIC RISK PROFILE IN PATIENTS WITH PSORIASIS BY METABOLIC SYNDROME STATUS: POOLED ANALYSIS FROM TWO PHASE 3 TRIALS
N. N.Mehta *, M. G.Lebwohl , A.Peserico , E.Fumero , A. B.Gottlieb , A. M.Mendelsohn , J.Myers , J.Parno , S. J.Rozzo , A.Menter (Bethesda, United States)
P079
SUSTAINED RESPONSES OF TREATMENT BY BRODALUMAB COMPARED TO USTEKINUMAB
L.Puig *, J.Hansen , V.Schultz Nielsen , E.Laffitte (Barcelona, Spain)
P080
SAFETY IN PATIENTS WITH LATENT TUBERCULOSIS (TB) TREATED WITH GUSELKUMAB AND ANTI-TB TREATMENTS IN THE PHASE 3 VOYAGE 1 & 2 TRIALS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS
L.Puig *, T.-F.Tsai , T.Bhutani , J.Uy , P.Ramachandran , M.Song , Y.You , M.Gooderham , M.Lebwohl (Barcelona, Spain)
P081
EFFICACY OF RISANKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS BY BASELINE CHARACTERISTICS AND PRIOR THERAPIES
B.Strober *, W.Valdecantos , T.Zhan , J.Lambert , A.Menter (Farmington, United States)
P082
MANAGAMENT OF SEVERE PSORIASIS WITH IL12/23 ANTAGONIST AFTER DEVELOPMENT OF TNF ANTAGONIST-INDUCED LUPUS
A.Vilkaite *, V.Kucinskiene , S.Valiukeviciene (Kaunas, Lithuania)
P083
EXPERIENCE ON THE USE OF PHOTOTHERAPY IN THE PEDIATRIC AGE AND COMPARISON WITH ITS USE IN THE ADULT POPULATION
J.Magdaleno-Tapial *, J.Ortiz-Salvador , C.Valenzuela-Oñate , M.Giacaman-von Der Weth , B.Ferrer-Guillén , M.García-Legaz Martínez , Á.Martínez-Domenech , D.Subiabre-Ferrer , P.Cornejo-Marí , J.Tracy-Joseph , A.Esteve-Martínez , A.Pérez-Ferriols (Valencia, Spain)
P084
TEM1657 IS A NEW SMALL MOLECULE FOR THE ORAL AND TOPICAL TREATMENT OF PSORIASIS
J.-F.Ginglinger *, P.Hannewald (Vandoeuvre, France)
P085
APREMILAST IN REAL PRACTICE: EXPERIENCE AND LEARNINGS FROM OUR 200 PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS IN SANTANDER
S.Armesto *, M.gonzalez vela , N.Palmou , M. T. A.Loste , M.Drake , M.Marcellan , C.lopez , C.gomez , B.castro , J.Mayorga , A.quintana , C.dURAN , M. A.gLEZ , R.Blanco , J.Crespo , M. A.gonzalez Gay , A.Illaro (Santander, Spain)
E-Posters
P100
ATOPIC LABIAL PIGMENTATION: A NEW DIAGNOSTIC FEATURE IN ASIAN PATIENTS WITH ATOPIC DERMATITIS
C.-Y.Lee , I.-H.Kang , K.-H.Jeong *, N. I.Kim , M. K.Shin (Seoul, Korea, Republic Of)
P101
ATYPICAL HAND, FOOT, AND MOUTH DISEASE
CAUSED BY COXSACKIEVIRUS A6 IN CHILDREN WITH ATOPIC DERMATITIS
I.Bae *, B. S.Shin , M.Kim , C.Na , H.Choi (Gwangju, Korea, Republic Of)
P102
TREAT TO TARGET IN PSORIASIS: A BELGIAN DEFINITION OF AN OUTCOME SCORE
L.Grine *, M.De La Brassinne , P.-D.Ghislain , T.Hillary , J.Lambert , S.Segaert , F.Willaert , J.Lambert (Ghent, Belgium)
P103
INCIDENCE OF CARDIOVASCULAR EVENTS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS TREATED WITH TILDRAKIZUMAB: POOLED ANALYSIS FROM A PHASE 2 AND TWO PHASE 3 TRIALS
R.Bissonnette *, P.Fernández-Peñas , L.Puig , A.Peserico , E.Fumero , A.Mendelsohn , S.Rozzo , A.Menter (Montreal, Canada)
P104
IMPROVEMENT IN ABSOLUTE PSORIASIS AREA AND SEVERITY INDEX SCORE THROUGH 3 YEARS OF CONTINUOUS TREATMENT WITH GUSELKUMAB IN THE VOYAGE 1 TRIAL
L.Puig *, K. B.Gordon , T.-F.Tsai , D.Thaci , M.Gooderham , S.Fakharzadeh , S.Li , Y.-K.Shen , K.Reich (Barcelona, Spain)
P105
LONG-TERM SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: POOLED ANALYSIS THROUGH 148 WEEKS FROM TWO PHASE 3 TRIALS
K.Reich *, D.Thaçi , I.Pau-Charles , A.Igarashi , M.Ohtsuki , M.Lebwohl , W.Cantrell , S.Rozzo , A.Blauvelt , L.Iversen (Hamburg, Germany)
P106
UNDERSTANDING TREATMENT EFFICACY USING PATIENT-LEVEL PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORES FROM RESURFACE 1 AND RESURFACE 2 PHASE 3 TRIALS
C.Ellis *, N.Korman , F.Murphy , L.Spelman , L.Puig , A.Mendelsohn , J.Parno , S.Rozzo , P.Yamauchi (Ann Harbor, United States)
P107
ACHIEVING AND MAINTAINING LONG-TERM OPTIMAL IMPROVEMENTS IN PATIENT-REPORTED SYMPTOMS, SIGNS, AND QUALITY OF LIFE AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH GUSELKUMAB: 3-YEAR DATA FROM VOYAGE 1
A.Blauvelt *, C.Han , K. A.Papp , C. E.Griffiths , P.Fernandez-Penas , D. N.Adam , S.Philipp , M.Song , Y.-K.Shen , A. B.Kimball (Portland, United States)
P108
MAINTENANCE OF RESPONSE WITH GUSELKUMAB FOR UP TO 3 YEARS’ TREATMENT IN THE PHASE 3 VOYAGE 1 TRIAL OF PATIENTS WITH PLAQUE PSORIASIS
C. E.Griffiths *, K. A.Papp , M.Song , B.Randazzo , S.Li , Y.-K.Shen , C.Han , A.Blauvelt (Manchester, United Kingdom)
P109
IMPACT OF QUALITY OF LIFE AFTER WITHDRAWAL AND RETREATMENT WITH IXEKIZUMAB: A POST HOC ANALYSIS OF A JAPANESE STUDY ON PATIENTS WITH PLAQUE PSORIASIS (UNCOVER-J)
H.Takahashi *, Z.Cai , R.Burge , B.Zhu , H.Torisu-Itakura , D. S.Shrom , D. A.Amato , J. Y. M.Koo (Obihiro, Japan)
P110
THE EFFICACY OF A GAIN-SWITCHED 311-NM TI:SAPPHIRE LASER IN TREATMENT OF PALMOPLANTAR PUSTULOSIS (PPP)
Y. W.Oh , J. H.Kim , D. H.Kim , H. S.Suh , Y. S.Choi * (Ulsan, Korea, Republic Of)
P111
BENEFITS OF ACHIEVING OF PATIENT-REPORTED SYMPTOM-FREE STATUS VS PASI 100 RESPONSE: ANALYSIS FROM THE VOYAGE-2 CLINICAL TRIAL
R.Bissonnette *, T.-F.Tsai , C.Han , M.Song , S.Li , S.McElligot , E.Muser , K. B.Gordon (Montreal, Canada)
P112
RELATIONSHIP BETWEEN PASI AND DLQI SCORES AND ANXIETY/DEPRESSION IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH BRODALUMAB IN THE AMAGINE-1 TRIAL
A.Chiricozzi *, M.Faurby , J.Hansen , V.Schultz Nielsen , J.-P.Lacour (Pisa, Italy)
P113
CORRELATION AND DIFFERENTIATION BETWEEN THE PSORIASIS SYMPTOM INVENTORY (PSI), PSORIASIS AREA AND SEVERITY INDEX (PASI), AND DERMATOLOGY LIFE QUALITY INDEX (DLQI)
L.Iversen *, M.Faurby , V.Schultz Nielsen , M.Augustin (Aarhus, Denmark)
P114
CONSISTENCY OF RESPONSE MAINTAINED ACROSS DEMOGRAPHIC SUBGROUPS OF PSORIASIS PATIENTS TREATED WITH GUSELKUMAB FOR UP TO 3 YEARS IN THE VOYAGE 1 AND 2 TRIALS
A.Blauvelt *, K.Reich , L.Spelman , J.Bagel , R.Bissonnette , S.Gerdes , S.Fakharzadeh , M.Song , Y.-K.Shen , K. B.Gordon (Portland, United States)
P115
LONG-TERM EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS WHO WERE RESPONDERS AT WEEK 28: POOLED ANALYSIS THROUGH 148 WEEKS FROM TWO PHASE 3 TRIALS
D.Thaçi *, L.Iversen , I.Pau-Charles , A.Igarashi , M.Ohtsuki , S.Rozzo , M.Lebwohl , W.Cantrell , A.Blauvelt , K.Reich (Lübeck, Germany)
P116
NAIL OUTCOME IMPROVEMENTS WITH CERTOLIZUMAB PEGOL IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALS
A. B.Gottlieb *, D.Thaçi , C.Leonardi , Y.Poulin , S.Kavanagh , M.Boehnlein , K.Reich (New York, United States)
P117
EFFICACY OF CONTINUED CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WHO INADEQUATELY RESPOND IN THE FIRST 16 WEEKS: RESULTS FROM THE CIMPACT TRIAL
M.Augustin *, M.Lebwohl , V.Piguet , H.Sofen , A.Blauvelt , L.Peterson , C.Arendt , M.Boehnlein , R. B.Warren (Hamburg, Germany)
P118
ASSOCIATIONS BETWEEN IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND ABSOLUTE PSORIASIS AREA AND SEVERITY INDEX SCORE: RESULTS FROM VOYAGE 2
S.Tyring *, C.Han , Y.You , D.Thaçi , M.Song , S.Fakharzadeh , L.Puig (Webster, United States)
P119
LONG-TERM EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS WHO WERE PARTIAL RESPONDERS OR NON-RESPONDERS TO ETANERCEPT: RESULTS FROM THE RESURFACE 2 PHASE 3 TRIAL THROUGH 148 WEEKS
L.Iversen *, K.Reich , C.Griffiths , A.Peserico , A.Kimball , I.Pau-Charles , A.Blauvelt , D.Thaçi (Aarhus, Denmark)
P120
LUPUS PERNIO WITH 5 YEARS OF DECREASED VISUAL ACUITY
W.Abdelli , F.Rebhi , M.Ben Slimane , S.Youssef , N.Doss *, K.Jaber , M. R.Dhaoui (Tunis, Tunisia)
P121
CHILDHOOD PSORIASIS: A DESCRIPTIVE STUDY
F.Rabhi *, M.Ben Slimen , S.Youssef , K.Jaber , M. R.Dhaoui (Tunis, Tunisia)
P122
ATYPICAL PITYRIASIS ROSEA PRESENTING WITH VESICULAR LESIONS
A.Pessoa *, V.Maiolini , D.Obadia , S.Carneiro , A.Brotas (Rio de Janeiro, Brazil)
P123
FACIAL PSORIASIS IN CHILDHOOD
F.Rabhi , W.Abdelli , S.Youssef , N.Doss *, K.Jaber , M. R.Dhaoui (Tunis, Tunisia)
P124
LUPUS VULGARIS
M.H 15 YEAR OLD FEMALE SWEDA SYRIA
THE COMPLAIN BEGAN SEVEN YEARS AGO WITH CHRONIC ULCERS WITH FACIAL ERYTHMA AND UPPER LIP
ENLARGEMENT.
N.Aljebae , M.Aalamatori * (Sweda, Syrian Arab Republic)
P125
INCREASE OF CARDIOVASCULAR RISK IN THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
D.Romero-Pérez , I.Belinchón-Romero *, P.Bellot , R.Francés , F.Marco , J. M.Ramos (Alicante, Spain)
P126
PERIODONTAL DISEASE IN CHILEAN PSORIATIC PATIENTS AND S100A8 MOLECULAR ANALYSIS IN GINGIVAL CREVICULAR FLUID.
F.Valenzuela *, D.Carvajal , J.Fernández , A.Fernández , C.Jimenez , M.Hernández (Santiago, Chile)
P127
CENTRAL OBESITY IN JUVENILE PSORIASIS
F.Rabhi , I.Benlagha , S.Youssef , N.Doss *, K.Jaber , M. R.Dhaoui (Tunis, Tunisia)
P128
OVERWEIGHT IN CHILDHOOD PSORIASIS: A CASE-CONTROL STUDY
F.Rabhi , I.Benlagha , S.Youssef , N.Doss *, K.Jaber , M. R.Dhaoui (Tunis, Tunisia)
P129
CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF HIV-PSORIASIS CASES
F.Úsuga Úsuga *, M.Velásquez Lopera , O.Quirós Gómez , L. A.Correa (Medellín, Colombia)
P130
DETERMINING SURGICAL VERSUS NONSURGICAL OPTIONS FOR AN UNKNOWN INFLAMMATORY DISORDER IN A CHARCOT FOOT PATIENT
T.Brookshier * (Pomona, United States)
P131
UPADACITINIB IMPROVED PATIENT-REPORTED SLEEP IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
K.Reich *, M.Liu , B.Calimlim , H. D.Teixeira , J. I.Silverberg (Hamburg, Germany)
P132
PUSTULAR PSORIASIS IN TUNISIA : A 10-YEAR REVIEW
I.Chabchoub , H.Hammami , A.Zaouak , S.Fenniche * (Tunis, Tunisia)
P133
VALIDITY OF DIAGNOSTIC CODES FOR IDENTIFICATION OF PSORIASIS PATIENTS IN KOREA
H.-J.Park *, S. P.Ham , J. H.Oh , H. J.Park , J. U.Kim , H. Y.Kim , S. Y.Jung , S. Y.Choi , J. E.Seol , H.Kim , M. S.Kim , U. H.Lee , M.Choi (Goyang, Korea, Republic Of)
P134
COST EFFECTIVENESS ANALYSIS OF BIOLOGICS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN HONG KONG
J.Fung , W.Chan , J.Wu , H.Pang * (Pok Fu Lam, Hong Kong)
P135
HIDRADENITIS SUPPURATIVA HURLEY II/III: HISTOPATHOLOGICAL EVALUATION IN 26 PATIENTS
S.Carneiro *, G.Verardino , M.Chaves , A.Pessoa , R.Souto (Rio de Janeiro, Brazil)
P136
EFFECTS OF SOD3-MSC IN A MURINE ATOPIC DERMATITIS-LIKE SKIN INFLAMMATION MODEL
T.-Y.Kim * (Seoul, Korea, Republic Of)
P137
MELANOMA AND SQUAMOUS CELL CARCINOMA IN PATIENT WITH SEVERE PUSTULAR PSORIASIS
F.Rabhi *, S.Youssef , M.Ben Slimen K.Jaber , M. R.Dhaoui (Tunis, Tunisia)
P138
TNF-ALPHA, IL-6 AND IL-8 IN PATIENTS WITH IDIOPATHIC TYPE OF KAPOSI'S SARCOMA
K.Khalidova *, G.Ismailova (Tashkent, Uzbekistan)
P139
EDUCATION FOR PATIENTS WITH PSORIASIS IN KOREA
H. J.Song * (Seoul, Korea, Republic Of)
P140
CHILHOOD PSORIASIS : A STUDY OF 306 CASES FROM SOUTH TUNISIA
M.Ben Rejeb *, F.Frikha , M.Mseddi , E.Bahloul , S.Boudaya , M.Amouri , H.Turki (Sfax, Tunisia)
P141
TREATMENT WITH TNF-Α INHIBITOR RECTIFIES M1 MACROPHAGE POLARIZATION
FROM BLOOD CD14+ MONOCYTES IN PATIENTS WITH PSORIASIS INDEPENDENT
OF STAT1 AND IRF-1 ACTIVATION
C.-H.Hong *, C.-H.Lee , S.-H.Lin (Taipei, Taiwan)
P142
TRANSCRIPTOMIC ANALYSIS OF EARLY RESPONSE TO IXEKIZUMAB TREATMENTS IN CHINESE PSORIATIC PATIENTS
Y.Ren *, L.Liu , C.Zhu , X. Yin , M.Zheng (Hangzhou, China)
P143
INTERACTION BETWEEN MUCOSAL AND CUTANEOUS IMMUNE RESPONSES TO STREPTOCOCCUS PYOGENES IN PSORIASIS: A ROLE FOR ANTIGEN SPECIFIC IGA AND CLA+ T CELLS
M.Ferran *, C.de Jesus , A.Chiriac , A.Celada , R. M.Pujol , L. F.Santamaria-Babi (Barcelona, Spain)
P144
THE IL17F HIS161ARG POLYMORPHISM POTENTIALLY AFFECTS SUSCEPTIBILITY OF PSORIASIS THROUGH INCREASED PRODUCTION OF INTERLEUKIN-17F
Y. B.Choe *, J. Y.Hong , J. H.Kim , J. R.Hong , H. I.Cheon , M. S.Hur , Y. W.Lee , K. J.Ahn (Seoul, Korea, Republic Of)
P145
CLINICAL FEATURES AND FREQUENCY OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PSORIATIC PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS
J.Youn *, J.Lee , H.Suh , M.Park , J.Ahn , Y.Youn (Seoul, Korea, Republic Of)
P146
MANAGEMENT OF PUSTULAR PSORIASIS DURING PREGNANCY: REPORT OF 3 CASES
A.Zaouak *, O.Magdoud , S.Ben Jannet , H.Hammami , S.Fenniche (Tunis, Tunisia)
P147
PSORIASIS AND COMORBIDITIES
S.Miladi *, S.Boudaya , E.Bahloul , A.Masmoudi , M.Mseddi , M.Amouri , H.Turki (Sfax, Tunisia)
P148
CHLORPROMAZINE-INDUCED KOEBNER PHENOMENON IN PSORIASIS
S.Maghfour *, N.Nebli , Y.Soua , M.Youssef , H.Belhadjal , J.Zili (Monastir, Tunisia)
P149
A CASE OF GENERALIZED PUSTULAR PSORIASIS RELATED TO ORAL TERBINAFINE
A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche (Tunis, Tunisia)
P150
PUSTULAR PSORIASIS AND TELOGEN EFFLUVIUM: WHICH IS INCRIMINATED THE DRUG OR THE DISEASE?
A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche (Tunis, Tunisia)
P151
PEDIATRIC GENERALIZED PUSTULAR PSORIASIS: A SEVERE SKIN CONDITION
A.Zaouak *, O.Magdoud , S.Ben Jannet , H.Hammami , S.Fenniche (Tunis, Tunisia)
P152
TISSUE EXPRESSION OF AQUAPORIN 3 IN PSORIATIC PATIENTS BEFORE VS. AFTER TREATMENT WITH ORAL RETINOIDS AND PHOTOCHEMOTHERAPY
S.Ramadan , O.Abu Zeid , N.Dorgham , M.Assaf , M.Amer *, H.Mashaly (Cairo, Egypt)
P153
THE PILOT STUDY OF HLA-CW06 ALLELE FREQUENCY IN LITHUANIAN PATIENTS WITH PLAQUE PSORIASIS
K.Židonienė *, I.Sakalauskienė , S.Valiukevičienė , V.Kučinskienė , L.Kučinskas , R.Ugenskienė , A.Vitkauskienė (Kaunas, Lithuania)
P154
LINK BETWEEN PSORIASIS AND TUBERCULOSIS
N.Tsankov *, I.Grozdev (Sofia, Bulgaria)
P155
A RARE CASE OF AMOXICILLIN INDUCED PSORIASIS
A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche (Tunis, Tunisia)
P156
ONYCHOMADESIS SECONDARY TO INFECTION AND ORAL RETINOIDS IN A PSORIATIC PATIENT
A.Zaouak *, A.Chamli , H.Hammami , S.Fenniche (Tunis, Tunisia)
P157
TRANSIENT PHOTOTOXIC SKIN REACTION IN PSORIATIC PATIENT TREATED WITH SELECTIVE PHOSPHODIESTERASE 4 INHIBITOR WITHOUT DISCONTINUING THE USE OF SYSTEMIC DRUGS
S.Valiukevičienė *, A.Bubilaitė , D.Stragytė (Kaunas, Lithuania)
P158
HEPATIC AND MUSCULOSKELETAL DISEASE IN PSORIASIS
P.Gisondi *, C.Virga , G.Girolomoni (VERONA, Italy)
P159
SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR (BMS-986165) IMPACT ON QUALITY OF LIFE (QOL) IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PSO) IN A PHASE 2 TRIAL AS ASSESSED BY THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
D.Thaçi *, K.Papp , K.Gordon , A.Morita , M.Gooderham , P.Foley , R.Kisa , A.Napoli , S.Kundu , S.Banerjee (Luebeck, Germany)
P160
A CASE OF SUICIDE IN A SEVERE PSORIASIS PATIENT EXACERBATED AFTER PHOTOTHERAPY
I.Bae *, B. S.Shin , M.Kim , C.Na , H.Choi (gwangju, Korea, Republic Of)
P161
PSORIASIS SEVERITY CALCULATION AND NEW SPANISH COMORBIDITY SCREENING ALGORITHM EASED BY A SMARTPHONE APP. OPTIMISATION OF TIME IN DERMATOLOGIC CONSULTATION
E.Escario *, A.Escario (ALBACETE, Spain)
P162
EFFICACY OF SECUKINUMAB IN BOTH BIOLOGIC-NAIVE OR NON-NAIVE PSORIASIS PATIENTS: POST-HOC FINDINGS FROM THE IPSI PSO STUDY
M.-A.Richard *, P.Joly , S.Aractingi , P.Auquier , S.Le Guen , E.Mahé (Marseille, France)
P163
EVALUATION OF THE SECUKINUMAB EFFICACY IN SPECIFIC PSORIASIS LOCATIONS USING THE PSORIASIS SIMPLIFIED INDEX
M.-A.Richard *, P.Joly , S.Aractingi , P.Auquier , S.Le Guen , E.Mahé (Marseille, France)
P164
PSORIASIS SYMPTOM INVENTORY (PSI) TO ASSESS THE SEVERITY OF PLAQUE PSORIASIS SYMPTOMS AND DIFFERENCES IN PATIENT-REPORTED OUTCOMES BETWEEN BRODALUMAB AND USTEKINUMAB
M.Augustin *, V.Schultz Nielsen , J.Hansen , L.Iversen (Hamburg, Germany)
P165
BIOLOGIC THERAPY OF PSORIASIS IN HAEMODIALYZED PATIENTS
S.Urbancek *, T.Pecova , K.Vorcakova , K.Martinaskova , M.Bielikova (Banska Bystrica, Slovakia)
P166
USE OF SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN KOREA
G.-W.KIM *, D.-L.Ha , H.-S.Kim , H.-C.Ko , M.-B.Kim , B.-S.Kim (Busan, Korea, Republic Of)
P167
RESPONSE OF SUPERIMPOSED LINEAR PSORIASIS TO ADALIMUMAB
M.Anodal *, P.Liarde , G.Pellerano , C.Chiappe (Buenos Aires, Argentina)
P168
EFFECTIVITY OF ADALIMUMAB. A REAL-LIFE, LONG-TERM STUDY
J. M.Ortiz Salvador *, J. L.Sánchez Carazo , A.Pérez Ferriols (Valencia, Spain)
P169
CHOLESTASIS IN PSORIASIS: A THERAPEUTIC CHALLENGE
A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche (Tunis, Tunisia)
P170
DIAGNOSIS OF PSORIASIS FROM KOEBNER PHENOMENON
P.Liarde *, M.Anodal , G.Pellerano , C.Chiappe (Buenos Aires, Argentina)
P171
INFECTIONS IN LIBYAN PATIENTS UNDER IMMUNOSUPPRESSIVE DRUGS
I.Almukahal *, H.Ehousana (Benghazi, Libya)
P173
LOW DOSE NALTREXONE THERAPY FOR PSORIASIS: OPEN-LABEL CASE SERIES
A.Egeberg *, L.Weinstock , J.Cottel , L.Aldridge (Copenhagen, Denmark)
P174
WHOLE EXOME SEQUENCING-BASED APPROACH IDENTIFIED NEW SUSCEPTIBILITY LOCI FOR PSORIASIS IN KOREAN POPULATION
K.-H.Jeong *, S.-K.Kim , M. K.Shin , N. I.Kim (Seoul, Korea, Republic Of)
P175
SECUKINUMAB IS ASSOCIATED WITH SUSTAINED IMPROVEMENT IN PATIENTS’ QUALITY OF LIFE UP TO YEAR 5: RESULTS OF A RANDOMIZED EXTENSION OF THE PHASE III ERASURE AND FIXTURE TRIALS
R.Langley *, B.Sigurgeirsson , J.Szepietowski , T.-F.Tsai , A.de Vera , P.Charef , I.Gilloteau , R.You , I.Hampele (Halifax, Nova Scotia, Canada)
P176
NOVEL ANTI-INFLAMMATORY EMOLLIENT GEL: ASSESSMENT OF EFFICACY IN SLS PROVOKED/IRRITATED SKIN
M.Lukic *, I.Pantelic , S.Savic (Belgrade, Serbia)
P177
CHIKUNGUNYA, DENGUE AND ZIKA INFECTIONS EXACERBATE PSORIASIS IN PATIENTS UNDER BIOLOGICAL THERAPY
K. M.Araujo , A. L.Bressan , L. A.Abulafia * (Rio de Janeiro, Brazil)
P178
THE INFLAMATORY MARKERS AND THE CORONARY ARTERIES DISEASES IN PSORIATIC PATIENTS
M.Vargu *, P.Vargu (Tirana, Albania)
P179
EVALUATION OF MICROALBUMINURIA AS AN INDICATOR OF RENAL IMPAIRMENT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
F.Ladeira de Oliveira , A.Bressan , L.Azulay - Abulafia * (Rio de Janeiro, Brazil)
P180
PREVALENCE OF HASHIMOTO'S THYROIDITIS IN PATIENTS WITH PSORIASIS AND ITS ASSOCIATION WITH TYPE AND FORM OF THE DISEASE
A. A.Tanaka *, P. T. S. Zakszewski , M. M.Coimbra , T. L.skare , J.Valduga , L. B.rebeiko (Curitiba, Brazil)
P181
CHARACTERISTICS OF PATIENTS WITH PSORIASIS IN A DERMATOLOGY CENTER IN BOGOTÁ COLOMBIA.
D.Castillo Molina *, D. M.Martínez Zúñiga , D. E.Castillo Saavedra , D. P.Cantillo Palencia (Bogotá, Colombia)
P182
ANNUAL ECONOMIC BURDEN OF MEDICAL ATENTION IN PATIENTS WITH MODERATE AND SEVERE ATOPIC DERMATITIS IN A THIRD LEVEL HOSPITAL IN MEXICO CITY: A PRELIMINAR REPORT
D. O.Perez-Rojas , E.Guevara-Sanginés * (Mexico city, Mexico)
P183
MICROSCOPIC EXAMINATION OF NAIL CLIPPINGS FROM PATIENTS WITH PALMOPLANTAR PUSTULOSIS.
A. A.Tanaka *, B.Werner , C.Farris , C.Tornesy (Curitiba, Brazil)
P184
PSORIASIS TREATMENT AND PATIENTS SATISFACTION IN CLINICAL PRACTICE
A. A.Tanaka *, C.Orso , V. R.Padilha , C.Medaglia , J. V.Schimith (Curitiba, Brazil)
P185
CO-ENCAPSULATION OF IMMUNO-ACTIVE AND ANTI-INFLAMMATORY MOLECULES IN A PICKERING EMULSION FOR ATOPIC DERMATITIS THERAPEUTIC APPROACH
M.Sintes , M.Beladjine , D.Boccara , M.Mimoun , J.-D.Bouaziz , A.Benssussan , M.Bagot , F.Agnely , N.Huang , L.Michel * (Paris, France)
P186
PERIODONTAL DYSBIOSIS IN PLAQUE PSORIASIS PATIENTS
G.León-Dorantes *, J. A.Arreguin-Cano (Mexico City, Mexico)
P187
EXPRESSION OF METALLOPROTEASES AND HEPARANASES IN PSORIASIS
M.Fatima Muaccad Gama Wagner *, L. K.Matsuka Oyafuso , T.Rachell Theodoro , M. A. da Silva Pinha , G. Fernandes Conrado , G.Milani (Sao Paulo , Brazil)
P188
SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS: INDIVIDUAL PATIENT META-ANALYSIS OF FOUR PHASE 3 TRIALS IN 2049 PATIENTS
A.Gottlieb *, P.Mease , B.Kirkham , P.Nash , A.Balsa , B.Combe , J.Rech , M.Ruvie , G.Ligozio , K.Abrams , L.Pricop (New York, United States)
P189
SECUKINUMAB PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN ACTIVE PSORIATIC ARTHRITIS PATIENTS: 52-WEEK RESULTS FROM FUTURE 5 STUDY
P.Mease *, D. V. D.Heijde , R.Landewé , S.Mpofu , P.Rahman , H.Tahir , A.Singhal , E.Boettcher , S.Navarra , X.Zhu , A.Readie , L.Pricop , K.Abrams (Seattle, United States)
P190
PERSPECTIVES OF COLOMBIAN PATIENTS WITH PSORIASIS ON ACCESS TO TREATMENT AND ITS REPERCUSSION ON THE SOCIAL ENVIRONMENT. AN EXPERIENCE OF FUNDAPSO.
F. A.Úsuga Úsuga *, G.Gutiérrez , O.Quirós Gómez , M.Velásquez Lopera (Medellín, Colombia)
P191
PATIENT WITH PSORIASIS, PSORIATIC ARTHRITIS AND HIDRADENITIS SUPPURATIVA TREATED WITH SECUKINUMAB: A CASE REPORT
A.Carija *, A.Bubic , N.Puizina Ivic (Split, Croatia)